A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

NCT07535437 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Ivonescimab
DRUG: Dato-DXd
DRUG: Osimertinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]